Quick Answer
Aardvark Therapeutics, Inc. reported Operating Income of -$62.73 million for fiscal year 2025.
Aardvark Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$62.73M | -175.3% |
| 2024 | -$22.79M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$17.70M | -247.7% | -11.7% |
| June 30, 2025 | -$15.85M | -161.0% | -51.4% |
| March 31, 2025 | -$10.47M | -382.3% | -105.7% |
| September 30, 2024 | -$5.09M | — | +16.2% |
| June 30, 2024 | -$6.07M | — | -179.7% |
| March 31, 2024 | -$2.17M | — | — |
- Aardvark Therapeutics, Inc. showed a decrease of -175.3% in Operating Income compared to the prior fiscal year.
- Over the 2024–2025 period, Aardvark Therapeutics, Inc.’s operating income has declined by 175.3% (from -$22.79 million to -$62.73 million).
- The most recent figure is from Aardvark Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: